123 related articles for article (PubMed ID: 3018954)
1. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
Sills T; Heptinstall S
Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
3. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
[TBL] [Abstract][Full Text] [Related]
4. Platelet behaviour in normal pregnancy, pregnancy complicated by essential hypertension and pregnancy-induced hypertension.
Morrison R; Crawford J; MacPherson M; Heptinstall S
Thromb Haemost; 1985 Oct; 54(3):607-11. PubMed ID: 3937260
[TBL] [Abstract][Full Text] [Related]
5. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
6. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
8. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and dazoxiben as inhibitors of platelet behaviour: modification of their effects by agents that alter cAMP production.
Sills T; Cowley AJ; Heptinstall S
Thromb Res; 1986 Apr; 42(1):91-8. PubMed ID: 3010495
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
Menys VC; Davies JA
Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403
[TBL] [Abstract][Full Text] [Related]
11. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
12. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Schumacher WA; Lucchesi BR
J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
[TBL] [Abstract][Full Text] [Related]
13. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
14. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man.
Jones EW; Cockbill SR; Cowley AJ; Hanley SP; Heptinstall S
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):39S-44S. PubMed ID: 6401999
[TBL] [Abstract][Full Text] [Related]
15. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
16. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
[TBL] [Abstract][Full Text] [Related]
17. [Effects of imazodan and dazoxiben on cAMP levels and PGI2 production in cultured bovine aortic endothelial cells].
Jiang YY; Long K; Sheng ML
Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):421-4. PubMed ID: 2559580
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
20. The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals.
Cowley AJ; Jones EW; Carter AJ; Hanley SP; Heptinstall S
Br J Clin Pharmacol; 1985 Jan; 19(1):1-8. PubMed ID: 2983748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
